As the demand for COVID vaccines decreases worldwide, Moderna is planning to release a RSV vaccine, pending U.S. approval.
Moderna posted a narrower-than-expected loss for the first quarter as the company's cost-cutting efforts took hold and sales ...
The drugmaker is optimistic about higher sales with new vaccines and a little help from AI in the coming years.
Among their more prominent programs, Moderna is developing a vaccine-based treatment for solid tumors. Moderna's personalized neoantigen vaccine, mRNA-4157, has shown promising results in clinical ...
A new study from the CDC states that there is no data to support an association between the COVID vaccines and sudden cardiac death among previously healthy young persons The COVID-19 vaccines are ...
Pfizer, Inc. on Wednesday forecast 2024 sales that could be as much as $5 billion below Wall Street expectations, driving shares down 9% to a 10-year low. Moderna says its updated coronavirus ...
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window WASHINGTON -- The benefits of combination vaccines may seem ...
, opens new tab said on Thursday it had paused its plans to build a vaccine manufacturing facility in Kenya, following a post-pandemic decline in demand for COVID-19 vaccines. The move is in line ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. US biotech Moderna has put plans to build a vaccine plant in Kenya on hold, in a sign that moves to invest ...
One of the world’s top vaccine-makers is partnering with a major AI company to advance medicine — and its chief executive is excited. Moderna and OpenAI announced an ongoing partnership ...